SCHEMBL1608448

SCHEMBL1608448

COc1cccc(-c2nnc(-c3cnc(F)c(C)c3)o2)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 8/20 0.57
▸ RAB9A P51151 8/20 0.57
▸ SMN1; SMN2 Q16637 6/20 0.57
▸ TP53 P04637 6/20 0.57
▸ HPGD P15428 5/20 0.57
▸ ALDH1A1 P00352 5/20 0.57
▸ KMT2A Q03164 3/20 0.57
▸ MAPT P10636 3/20 0.57
▸ MEN1 O00255 2/20 0.57
▸ KDM4E B2RXH2 6/20 0.56
▸ TDP1 Q9NUW8 2/20 0.56
▸ NPSR1 Q6W5P4 1/20 0.56
▸ NOTUM Q6P988 2/20 0.50
▸ POLB P06746 1/20 0.49
▸ CASP3 P42574 1/20 0.48
▸ SENP7 Q9BQF6 1/20 0.48
▸ LMNA P02545 1/20 0.45
▸ HTT P42858 1/20 0.45
▸ PTK2 Q05397 1/20 0.45
▸ HSD17B10 Q99714 3/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1608464 0.85 RAB9A (0.61) NPC1RAB9ASMN1; SMN2TP53HPGD
SCHEMBL1181062 0.82 KDM4E (0.78) NPC1RAB9ASMN1; SMN2TP53HPGD
SCHEMBL1251118 0.82 NPC1 (0.62) NPC1RAB9ASMN1; SMN2TP53HPGD
SCHEMBL1608540 0.81 NPC1 (0.67) NPC1RAB9ASMN1; SMN2TP53KMT2A
SCHEMBL19685292 0.78 NPC1 (0.69) NPC1RAB9ASMN1; SMN2TP53HPGD
SCHEMBL3250240 0.77 NPC1 (0.72) NPC1RAB9ASMN1; SMN2TP53HPGD
SCHEMBL1251096 0.76 NPC1 (0.60) NPC1RAB9ASMN1; SMN2TP53KMT2A
SCHEMBL10054151 0.76 KDM4E (0.69) NPC1RAB9ASMN1; SMN2TP53HPGD
SCHEMBL27630742 0.75 NPC1 (0.68) NPC1RAB9ASMN1; SMN2TP53HPGD
SCHEMBL1423305 0.74 NPC1 (0.74) NPC1RAB9ASMN1; SMN2TP53HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110081297-A1 Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles MERCK & CO. INC. 2011-04-07 — — US claimed
US-20110081297-A1 Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles MERCK & CO. INC. 2011-04-07 — — US disclosed
US-20110081297-A1 Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles MERCK & CO. INC. 2011-04-07 — — US disclosed
US-20110081297-A1 Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles MERCK & CO. INC. 2011-04-07 — — US disclosed
WO-2009146343-A1 NOVEL SUBSTITUTED PYRAZOLES, 1,2,4-OXADIAZOLES, AND 1,3,4-OXADIAZOLES MERCK & CO., INC. (US) 2009-12-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110081297-A1 Novel Substituted Pyrazoles, 1,2,4-Oxadiazoles, and 1,3,4-Oxadiazoles APP, PSEN1, BACE1 NPC1 129/4885RAB9A 4026/4885SMN1; SMN2 2239/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback